企業プロフィール
Prime Medicine 株価・ニュース・カタリスト
- ティッカー:
- PRME
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
3.17 USD (+2.59%)
終値
最終更新: 2026年8月17日
580M USD
時価総額
株価変動の要因
As of Aug 17, 2026, PRME closed up 2.59% at $3.17. No new same-company headline was identified in the current news window.
企業概要
Prime Editing
Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo.
PM577
PM577 is an in vivo Prime Editing candidate designed to correct disease-causing mutations in the liver for Wilson disease.
PM647
PM647 is an in vivo liver-directed program for alpha-1 antitrypsin deficiency and is approaching clinical development on a timeline similar to PM577.
Chronic Granulomatous Disease
PM359 is an ex vivo edited cell therapy for chronic granulomatous disease. Prime Medicine is continuing regulatory dialogue with the FDA regarding a potential BLA path.
今後のカタリスト
- IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026.
- IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026.
- Initial clinical data from PM577 and PM647 in 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。